The company had reported Rs 707 crore profit for the year-ago quarter.

Lupin had entered into an arrangement to acquire the company earlier this year.

Drugmakers have reported impairments, reduced revenue guidance, or stretched the payback time.

The business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.

In addition to growth in sales in respective markets, favourable currency movement has also helped Lupin to achieve high growth.

In the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzic...

Gavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...

Karvy downgraded their EPS by 7.3%/10.6% to Rs 65.8/Rs 72.8 for FY17E/FY18E respectively due to amortization on account of Gavis acquisition

Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.

The acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...

Lupin, one of India's top five pharmaceutical companies, is planning to make significant investments in Japan, the second biggest pharmaceu...

The acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....

Mumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.

With no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...

The loan, it’s understood, is not backed by hard collateral or claims on future cashflow, but based on pure credit assessment.

After a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.

The deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.